Hodgkin's disease: Kuwait experience

Medical Principles and Practice

Volumn 13, Issue 4, 2004, Pages 201-205

  Al Shemmari, Salem H ^a   Al Humood, Salah ^a   Ameen, Reem ^b   Kamlesh, Sajnani ^b   Nemec, J ^b   Varghese, Abraham ^b  

^a KUWAIT UNIVERSITY   (Kuwait)

^b KUWAIT CANCER CONTROL CENTER   (Kuwait)

Author keywords

Hodgkin's disease, treatment; Kuwait

Indexed keywords

BLEOMYCIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE SULFATE;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DEMOGRAPHY; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; STANDARDIZATION; SURVIVAL;

ADOLESCENT; ADULT; AGED; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HODGKIN DISEASE; HUMANS; KUWAIT; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 3042552230     PISSN: 10117571     EISSN: None     Source Type: Journal    
DOI: 10.1159/000078316     Document Type: Article

References (24)

1. Franchini G, Ambinder RF, Barry M: Viral disease in hematology; in American Society of Hematology (ASH) Educational Book, 2000, pp 409-423.
2. Hartage P, Devessa S, Fraumeni JF: Hodgkin's disease and non-Hodgkin's lymphoma; in Doll R, Fraumeni J, Muir C (eds): Trends in Cancer Incidence and Mortality Cancer Surveys. New York, Cold Spring Harbor Laboratory Press, 1944, pp 423-453.
3. Glaser SL, Swartz WG: Time trends in Hodgkin's disease incidence: The role of diagnostic accuracy. Cancer 1990;66:2196-2204.
4. Parkin DM, Whelan SL, Ferlay J: Cancer incidence in five continents. International Agency for Research on Cancer, IARC Scientific Publications No 143. Lyon, IARC, 1997, vol 7, pp 410-417.
5. Jaffe ES, Harris N, Diebold J, et al: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: A progress report. Am J Clin Pathol 1999;111(suppl 1):S8-S12.
6. Carbone P, Kaplan HS, Musshof K, Smithers DW, Tubiana M: Report of the committee on Hodgkin's disease staging. Cancer Res 1971;31:1860-1861.
7. Al-Shemmari S, Al-Humood S, Muralidharan KC, Varghese VA: Radiotherapy for early stage of Hodgkin's disease at Kuwait Cancer Control Center, Kuwait. Med Princ Pract 2002;11:147-149.
8. MacMahon B: Epidemiological evidence of the nature of Hodgkin's disease. Cancer 1957;10:1045-1054.
9. Canellos GP, Anderson JR, Propert KJ: Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992;327:1478-1484.
10. Canellos GP, Niedzwiecki D: Long-term follow-up of Hodgkin's disease trial. N Engl J Med 2002;346:1417-1418.
11. DeVita VT Jr, Serpick A: Combination chemotherapy in the treatment of Hodgkin's disease (abstract). Proc Am Assoc Cancer Res 1967;8:13.
12. Longo DL, Young RC, Wesley M, Hubbard SM, Duffey PL, Jaffe ES, DeVita VT Jr: Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol 1986;4:1295-1306.
13. Connors JM, Klimo P, Adams G, Burns BF, Cooper I, Meyer RM, O'Reilly SE, Pater J, Quirt I, Sadura A, Shustik C, Skillings J, Sutcliffe S, Verma S, Yoshida S, Zee B: Treatment of advanced Hodgkin's disease with chemotherapy: Comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: A report from the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1997;15:1638-1645.
14. Glick JH, Young ML, Harrington D, Schilsky RL, Beck T, Neiman R, Fisher RI, Peterson BA, Oken MM: Mopp/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: The 8-years results of the Intergroup trial. J Clin Oncol 1998;16:19-26.
15. Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, Green MR, Gottlieb A, Peterson BA: Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992;327:1478-1484.
16. Canellos GP: Is ABVD the standard regimen for Hodgkin's disease based on randomized CALGB comparison of MOPP, ABVD and MOPP alternating with ABVD? Leukemia 1996;10(suppl 2):S68.
17. Santoro A, Bonfante V, Viviani S, Devizzi L, Zanini M, Soncini F, Gaaspanini M, Valagussa P, Bonadonna G: Subtotal nodal versus involved field irradiation after 4 cycles of ABVD in early stage Hodgkin's disease (abstract). Proc Am Soc Clin Oncol 1996;15:415.
18. Horning SJ, Rosenberg SA, Hoppe RT: Brief chemotherapy (Stanford V) and adjuvant radiotherapy for bulky or advanced Hodgkin's disease: An update. Ann Oncol 1996;7(suppl 4):105-108.
19. Frei E III, Luce JK, Gamble G, Coltman CA Jr, Constanzi JJ, Talley RW, Monto RW, Wilson HE, Hewlett JS, Delaney FC, Gehan EA: Combination chemotherapy in advanced Hodgkin's disease: Induction and maintenance of remission. Ann Intern Med 1973;79:376-382.
20. Young RC, Canellos GP, Chabner BA, Hubbard SM, DeVita VT: Patterns of relapse in advanced Hodgkin's disease. Cancer 1978;42:1001-1007.
21. Prosnitz LR, Farber LR, Kapp DS, Scott J, Bertino JR, Fischer JJ, Cadmen EC: Combined modality therapy for advanced stage Hodgkin's disease: 15-year follow-up data. J Clin Oncol 1988;6:603-612.
22. Yahalom J, Ryu J, Straus DJ, Gaynor JJ, Meyers J, Caravelli J, Clarkson BD, Fuks Z: Impact of adjuvant radiation on the patterns and rate of relapse in advanced-stage Hodgkin's disease treated with alternating chemotherapy combinations. J Clin Oncol 1991;9:2193-2201.
23. Santoro A, Bonadonna G, Valagussa P, Zucali R, Viviani S, Villani F, Pagnani AM, Bonafante V, Musumeci R, Crippa F, Tess JDT, Banfi A: Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: Superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol 1987;5:27-37.
24. Bonadonna G, Valagussa P, Santoro A: Alternating non-cross resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. Ann Intern Med 1986;104:739-746.